PIK3C3 and neoplasm: Although pharmacological inhibitors of Vps34 are in development [97,98], our data suggest that those inhibitors selectively targeting the autophagy function of Vps34 may be more suitable to unleash anti-tumor immunity while minimizing the potential for systemic immune hyperactivation.